CLINUVEL

U.S. Expansion Supported by Strong Foundation

Financial Year Ended 30 June 2026

Investor Briefings: 27 August – 4 September 2026

ASX: CUV | Nasdaq: CUVL | Börse Frankfurt: UR9

Forward-looking statement

CLINUVEL GROUP

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "foresee," "intend," "likely," "may," "objective," "potential," "plan," "predict," "project," "seek," "should," "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include but are not limited to risks relating to: our ability to develop and commercialise pharmaceutical products; pandemics, epidemics, public health emergencies, geopolitical conflicts, trade restrictions, natural disasters and other disruptions affecting global supply chains, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran's Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks including the risk factors described in the Company's Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission, together with the Company's announcements lodged with the Australian Securities Exchange. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation except as required by applicable law, the rules of the Australian Securities Exchange, the U.S. Securities and Exchange Commission, Nasdaq, or other applicable regulatory requirements, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

FY2026

Financial performance

- disciplined and balanced approach
- second consecutive year of $100m+ total revenue
- 10 consecutive annual profits
- 9 consecutive annual dividends
- FX translation of US$ term deposits resulted in *unrealised* loss of $4m impacting net profit
- RD&I growth through controlled expenses
- $12m of FY2026 income tax prepaid

CONSOLIDATED ENTITY[1]	30 June 2026	Change
Revenues[2]	**A$94m**	**-1%**
Revenues plus Interest and Other Income	**A$101m**	**-4%**
Expenses	**A$53m**	**-0.5%**
Net Profit Before Income Tax Expense	**A$48m**	**-8%**
Net Profit After Income Tax Expense	**A$34m**	**-6%**
Cash Reserves[3]	**A$252m**	**+12%**
Basic Earnings per Share	**A$0.68**	**-6%**
Net Tangible Assets Backing per Share	**A$5.35**	**+12%**
Dividend per Share Declared	**A$0.05**	**Stable**

1. All figures released to the Australian Securities Exchange in Australian dollars (A$) for financial year ended 30 June 2026.
2. Revenues from ordinary activities, excluding interest and other income.
3. Cash Reserves equal Cash and cash equivalents plus Cash held in term deposits (i.e. short-term investments).

FY2026

Profitability

SCENESSE® in EPP[1] – profitability

revenues growth over a decade	10-year CAGR **31%**
expenses growth well controlled	10-year CAGR **18%**
net profit margin	**36%**
reinvestment RD&I	**34%**
return on equity	**13%**



1. Erythropoietic protoporphyria.



FY2026

Expenses

- Expenses well controlled at $A53m, lower than 5- year average forecast expenditures.
- Largest allocation of resources to R&D at 34% of total expenses; reduction reflects cyclical timing of CUV105 clinical program completion
- Rise in General and Admin. reflects one-off Nasdaq listing costs
- Communications and Marketing lower as discretionary costs reduced

FY2026

Strong balance sheet

Year ended 30 June	2025	2026	△
Total Assets	A$272m	**A$295m**	**+9%**
Total Liabilities • mainly trade creditors & tax • debt-free	A$31m	**A$22m**	**-28%**
Cash Reserves [1]	A$224m	**A$252m**	**+12%**

1. Cash Reserves finance key initiatives through re-investment
2. Investment in infrastructure
   - expansion of Singaporean RD&I facility
   - refurbishment of Egham, UK, office
3. Establishing manufacturing & supply chain integration
4. Development of VLRX-L next-generation peptide platform
5. Balance Sheet strength provides resilience & optionality

1. Cash Reserves equal Cash and cash equivalents plus Cash held in term deposits (i.e. short-term investments).

Assets & liabilities (A$m)



Cash reserves (A$m)



Profitable, focused, disciplined

Ten years profitable
- distribution of SCENESSE® for EPP
- Europe, U.S.A., Israel, UK, Canada

Strong balance sheet
- zero debt
- cash reserves A$252m (US$171m)
- >4 year OPEX cash runway

Nine years of dividends – FY2026 returning 9% of cash reserves increase

High potential pipeline

Building a sustainable, integrated biopharmaceutical company



HQ – transitioning from Australia to U.S.A.

Principal operations – U.S.A., Europe, UK, Singapore

Milestones

1999 – Incorporated in Australia upon acquisition of afamelanotide technology

2001 – Listed on Australian Securities Exchange; trades as CUV

2004 – Established ADR Level I, on U.S. OTC; Commenced trading on Börse Frankfurt (UR9)

2006 – Strategic refocus "one drug for one indication"

2016 – SCENESSE® distribution EU

2020 – SCENESSE® distribution USA

2021/22 – Expansion of Product Range & Clinical Program; First adolescent EPP patient treated

2025 – First phase III vitiligo trial fully recruited; EU maximum recommended dose removed

2026 – Commenced ADS Level II, traded on Nasdaq (CUVL); SCENESSE® distribution Canada

Expanding American presence

Significant opportunity to treat patients in need

Increased American investor interest

- Phase III vitiligo studies – systemic Rx [not immune suppressive]
- SCENESSE® in EPP – direct distribution across 129 U.S. and 5 Canadian centers – 190 targeted (2027)
- U.S. comprises >43% of global EPP revenues
- Nasdaq uplisting (ADS, Level II) – completed 20 July 2026
- Board considering full listing on Nasdaq / delisting ASX
- Head Office relocation to U.S. – from 1 January 2027
- Increase U.S. management team – 2027



Commercial product and pipeline: melanocortins



1. IS= infantile spasms; MS = multiple sclerosis; CNS = central nervous system.

Future outlook

Foundation of 20 years

Products, indications & healthcare solutions
- 2 pharmaceutical products
- 5 conditions
- 3 PhotoCosmetic product lines

Advancing RD&I
- novel sustained-release liquid peptide formulations (VLRX-L)

Capital management
- disciplined deployment of capital
- no dilutive capital raisings – 10 years
- debt free

Vitiligo Phase III top line data expected December 2026 is a key value driver

TAM and penetration figures are in U.S. dollars (US$). 1. EPP revenues in FY26. 2. CLINUVEL estimates, Vitiligo is year 1 and 2 in U.S.A..

Calendar & catalysts

	CY2026 H1	H2	**CY2027** H1	H2
SCENESSE®		Health Canada: Marketing Authorization decision √		
				EMA filing SCENESSE®: adolescent use in EPP
Phase III, CUV105 vitiligo	AAD'26 cases presented √	Top line results (Dec '26)	Complete results	
Phase III, CUV107 vitiligo	EMA Scientific Advice √	Start recruitment (Nov '26)	FDA vitiligo meeting	Recruitment completed
ACTH–NEURACTHEL®		EU: 1st filing(s) for marketing authorisation		
VLRX–L		Liquid controlled-release formulation first preclinical results √		
Pipeline			New peptides in liquid controlled-release preclinical data	
RD&I		VALLAURIX Singapore: complete construction of expanded RD&I Centre		
Finance, commercial	FY'26 Half Year Results (31 Dec '25) √	FY'26 Financial Year Results (30 Jun '26) √	FY'27 Half Year Results (31 Dec '26)	FY'27 Financial Year Results (30 Jun '27)
	Commercial update EPP-Vitiligo √	SEC review: Nasdaq, ADR upgrade √		

Plans and expected timelines are subject to change as part of running an active business in a volatile operating environment. In addition, product development and clinical studies can experience delays and the time periods of assessment of regulatory submissions can vary.

CLINUVEL

Thank you

Authorised for ASX release by the Managing Director on behalf of the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

Head of Investor Relations: Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries: https://www.clinuvel.com/investors/contact-us

Level 22, 535 Bourke Street, Melbourne – Victoria, Australia, 3000 | T +61 3 9660 4900 | F +61 3 9660 4909

www.clinuvel.com

ASX: CUV | Börse Frankfurt: UR9 | ADR Level II: CUVL